Type II diabetes is a chronic condition that affects the way our body metabolizes sugar. The body's important source of fuel is now becoming a chronic disease all over the world. It is now very necessary to identify the new potential targets for the drugs which not only control the disease but also can treat it. Support vector machines are the classifier which has a potential to make a classification of the discriminatory genes and non-discriminatory genes. SVMRFE a modification of SVM ranks the genes based on their discriminatory power and eliminate the genes which are not involved in causing the disease. A gene regulatory network has been formed with the top ranked coding genes to identify their role in causing diabetes. To further validate the results pathway study was performed to identify the involvement of the coding genes in type II diabetes. The genes obtained from this study showed a significant involvement in causing the disease, which may be used as a potential drug target.
Introduction
Support Vector Machine (SVM), a machine learning technique implied in the area of time series prediction and classification [31, 36] has widely been applied in the life science fields, especially in Bioinformatics. It can handle nonlinear classification tasks efficiently by mapping the samples into a higher dimensional feature space by using a nonlinear kernel function. Since the SVM approach is data-driven and modelfree, it has important discriminating power for classification. This characteristic of SVM is obvious in cases where the sample sizes are negligible and numerous variables are involved (high-dimensional space).
Expression profile come under such a category, which contain a large number of attributes (genes). This type of expression data is used to predict the type and occurrence of the disease in a patient [39] . An important aspect while analyzing such type of expression data is the feature selection or dimensionality reduction. Most algorithms lose their potency when genes are large in number with different time series data or dimensionality [7] .
To accomplish the task of dimensionality reduction a modified version of SVM known as SVMRFE (Support Vector Machine Recursive Feature Elimination) has been used in this work. SVMRFE was used to identify the most discriminatory target gene in four different microarray data samples of type II diabetes. These samples have been taken from the Gene Expression Omnibus database (GEO) [13] and Diabetes Genome Anatomy Project (DGAP) (http://www.diabetesgenome.org/). The idea was to build a model wherein the least important features (genes) can be eliminated at each iterative step based on the weight assigned to each gene through SVM. The genes identified through this approach were then classified as essential and non-essential genes. The protein-protein interaction of these non-essential genes revealed vital information regarding interacting proteins. Functional enrichment about these proteins shed a light on their regulatory pathways associated with type II diabetes which can be further explored and confirmed using experimental approach.
Materials and methods

Collection of data sample
71 samples from Pancreatic Islet and Skeletal muscle of Homo sapiens were collected from the GEO and DGAP. Out of these 37 samples are of normal human beings and 34 are of diabetic humans. Table 1 shows the detail description of each of the data sets which were undertaken for studies.
Fisher linear discriminant was applied to all the above-mentioned data sets to rank them based on the Fischer score [21] which was continued with a redundancy reduction step to reduce the redundant data in the microarray dataset [22] . The gene number present in each data set was still high. A t-test [3] with a significance level of 0.05 was applied to the datasets to filter out the genes which are not involved in causing type II diabetes. After this reduction step SVMRFE approach (with linear kernel function and 6 subsets of the training data) [24] was applied to train the data samples for 5 iterations. As a result, discriminatory genes based on the weighted ranking were obtained. The identified genes were identified as being essential and non-essential using the database of essential genes. A gene interaction and pathway analysis of the potential non-essential genes was performed to identify the novel targets for type II diabetes ( Fig. 1) 
Result and discussion
t-test analysis
For each of the T2D datasets, a t-test analysis was performed with a significance level of 0.05. As a result, there was a high dimensionality Table 2 ). The genes rejecting the null hypothesis were obtained for each of the data samples. Tables 3-6 show the corresponding p-values of all the genes which have rejected the null hypothesis at significance level of 0.05. The Figs. 2-5 represent graphically the p-value of all the genes in the four datasets under consideration. The p-value for most of the genes was above the significance level value of 0.05. This represents that these genes have almost the same expression value in the normal and diseased and may not be involved in causing the disease.
Identification of best-ranked genes from SVMRFE
The subsets of genes based on the p-value were given as an input to the support vector machine. Recursive Feature Elimination (RFE) is an iterative procedure for SVM classifier. The recursive feature elimination algorithm of the support vector machine assigns a weight to each gene. The weight was calculated based on the expression value of genes in the disease and the normal sample for all the dataset. The algorithm classified the genes (with a classification accuracy of 83.9%) based on the descending order of the weight. Then it generated the list of genes which were found to be the most discriminatory in the normal and disease samples (Tables 7-10). The outline for SVMRFE in the linear kernel is presented below:
Inputs: 
Identification of degree of essentiality and non-essentiality of genes
To identify significant and reliable targets, the work was concentrated on non-essential genes. Essential genes were ruled out based on the hits obtained from the Database of Essential Genes (DEG 10.9) (http:// tubic.tju.edu.cn/deg/) [46] . Essential genes sustain an organism. Therefore, having them as a potential gene target may induce side effects of the drugs. Hence, it is important to identify only the non-essential genes which may be used as a potential drug target. Tables 11-14 show the non-essential genes from the microarray dataset which is under study
Gene interaction studies
After obtaining the non-essential genes from the top ranked coding genes for each of the datasets, gene regulatory network was constructed using STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) database [40] . The study was mainly done to observe the interaction between non-essential protein-coding genes with other proteins which are a result of biochemical events and/or electrostatic forces [23] . The function and activity of a protein are often modulated by other proteins with which it interacts.
Gene regulatory network of dataset "GSE7146"
In this dataset, out of the ten best coding genes obtained through the SVMRFE approach, only 5 genes (ACP1, FCGR2B, SCNN1G, CCL27, and DLG3) showed interaction with other protein coding genes (Fig. 6) . The ACP1 showed a direct interaction with EPHA2, which is reported to increase the chance of myocardial infarction and reduce the survival rate of hyperglycemic mice [12] . LYN showed indirect interaction with ACP1 via EPHA2 and direct interaction with FCGR2B. Its kinase activation modulation has been reported to be a novel insulin receptor-potentiating agent. This potentiating agent produces a rapid-onset and a durable blood glucose-lowering activity in diabetic animals [32] . FCGR2B also showed direct interaction with PTPN6 which is been reported to negatively regulate insulin action on glucose homeostasis in the liver and muscle [44] . An analysis of DLG3 has shown its direct interaction with GRIN2A and GRIN2B. Both these genes have been reported to play a potential role in diabetes [11, 37, 42] . UBC has been reported to play a major role in the diabetes pathway [8, 16, 26] and its direct interaction with SCNN1G shows that SCNN1G may also play a role in diabetes pathway. CCL27 interacts with CCL25, a protein whose expression was shown to decrease significantly in diabetes [30] .
Gene regulatory network of dataset "human pancreatic islets from normal and type II diabetic subjects (A)"
Except for ABCC4 and FMO5, all the other four proteins showed a significant and strong interaction with other neighboring proteins ( Fig. 7) .
Purine Nucleoside Phosphorylase (PNP) and Nucleoside Phosphate Kinase (NPK) have reportedly played a major role in diabetes either by positive or negative metabolic regulation [9] . These two molecules also showed interaction with the HPRT1 and the CDA. Caveolin has already been reported to mediate insulin signaling thereby affecting the glucose uptake [6] . In the other subgroup network FUT3 has three direct neighbors: FUT1, FUT2, and B4GALT1 of which the B4GALT1 expression level has been shown to be affected by hyperglycemia [25] .
Gene regulatory network of the dataset "human pancreatic islets from normal and type II diabetic subjects (B)"
Both the protein coding genes in this dataset (RNASEK and APCDD1) have shown a significant interaction with the neighboring proteins (Fig.  8 ). The involvement of RNASEK in diabetes is still an unanswered question, but APCDD1 interaction with its neighbors shows that it may be involved in the pathophysiology of diabetes. LPAR6 (Lysophosphatidic Acid Receptor 6) interacting directly with APCCD1 has shown its activity with PPARγ which is a potential target for diabetes [38] . Aranda et al., in 2012 also showed that the DM/HG (Diabetes mellitus/High Glucose) [14] showed that alterations in LRP5 expression may be responsible for diabetes susceptibility. Therefore it may be a potential target for therapeutic intervention. It has been reported that Wnt/ LRP5 (lipoprotein receptor-related protein 5) signaling contributes to the glucose-induced insulin secretion in the islets [15] .
Gene regulatory network of dataset "human skeletal muscle-type II diabetes"
The two prominent protein coding genes (USP6NL and ProSAPiP1) as per SVMRFE analysis showed interaction with a different set of genes ( Fig. 9 ). This selective network of ProSAPiP1 has not been reported till now, for diabetes. The three genes (SOS1, EGFR, and EGF) in the interaction network of USP6NL have shown its significance in connection with diabetes. SOS1 has shown its association with reference to the insulin action [4] , in differential expression of EGFR which is a major impact on diabetes and associated diseases [1, 5, 27, 28, 41, 45] . Kasayama et al. [19] long back in 1989 reported that EGF deficiency occurs in diabetes mellitus hence insulin may be important in maintaining the normal level of EGF in the submandibular gland and plasma.
Functional enrichment of significant genes implying pathway analysis
To further validate the involvement of the identified genes in type II diabetes, pathway enrichment was considered. This was solely meant for all the interacting proteins with the identified significant protein(s).
The study was carried out using Biointerpreter, a web-based biological interpretation tool for Microarray data analysis (Genotypic Technology Pvt. Ltd., Bangalore, India). The pathway analysis showed that some of the interacting proteins were involved in pathways which were directly or indirectly associated with type II diabetes.
Pathway enrichment for the interacting proteins of the dataset "effect of insulin infusion on human skeletal muscle"
GRIN2A (Glutamate [NMDA] receptor subunit epsilon-1) and GRIN2B (Glutamate [NMDA] receptor subunit epsilon-2), the two Table 7 Best ranked genes for dataset "GSE7146".
Gene name G0/G1switch 2 Transducin-like enhancer of split 1 (E (sp1) homolog, Drosophila) Acid phosphatase 1, soluble DnaJ (Hsp40) homolog, subfamily C, member 1 Golgi-associated, gamma adaptin ear containing, ARF binding protein 2 Protein phosphatase 1, regulatory subunit 7 Interleukin 1 receptor-like 1 Discs, large homolog 5 (Drosophila) Cytochrome P450, family 4, subfamily F, polypeptide 2 Protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform (calcineurin A gamma) Gap junction protein, beta 3, 31 kDa (connexin 31) Diaphanous homolog 2 (Drosophila) Olfactory receptor, family 7, subfamily C, member 2 Solute carrier family 22 (organic anion transporter), member 6 Serine peptidase inhibitor, Kazal Type II (acrosin-trypsin inhibitor) Chemokine (C-C motif) ligand 27 Dynein, axonemal, intermediate chain 2 Junctophilin 2 Kallikrein-related peptidase 12 S100 calcium binding protein A12 Discs, large homolog 3 (neuroendocrine-dlg, Drosophila) Sodium channel, non-voltage-gated 1, gamma subunit ST6 (alpha-N-acetyl-neuraminyl-2, 3-beta-galactosyl-1, 3)
-N-acetylgalactosaminide alpha-2, 6-sialyltransferase 5 Fc fragment of IgG, low affinity IIb, receptor (CD32) Best ranked genes for dataset "human pancreatic islets from normal and type II diabetic subjects (B)".
Gene name
Adenomatosis polyposis coli down-regulated 1 Ribonuclease, RNase K Table 10 Best ranked genes for dataset "human skeletal muscle-type II diabetes".
Protocadherin beta 3 Leucine zipper, putative tumor suppressor family member 3 USP6 N-terminal like Ubiquitously transcribed tetratricopeptide repeat containing, Y-linked Table 11 Non-essential genes for dataset "GSE7146".
Gene symbol
Gene name G0S2 G0/G1switch 2 ACP1
Acid phosphatase 1, soluble CCL27
Chemokine (C-C motif) ligand 27 JPH2 Junctophilin 2 KLK12
Kallikrein-related peptidase 12 S100A12 S100 calcium binding protein A12 DLG3 Discs, large homolog 3 (neuroendocrine-dlg, Drosophila) SCNN1G
Sodium channel, non-voltage-gated 1, gamma subunit ST6GALNAC5 ST6 (alpha-N-acetyl-neuraminyl-2, 3-beta-galactosyl-1, 3) -N-acetylgalactosaminide alpha-2, 6-sialyltransferase 5 FCGR2B
Fc fragment of IgG, low-affinity IIb, receptor (CD32) proteins interacting mainly with the identified protein DLG3 have been shown to be involved in 3 different pathways viz. Neuroactive ligandreceptor interaction, circadian entrainment and Long-term potentiation (Fig. 10 ). The proteins present in the Neuroactive ligand-receptor interaction have shown a significant role in the pathobiology of obesity and type II diabetes [10] . The second pathway, circadian entrainment is the biological process that displays an endogenous oscillation of about 24 h. Studies show that exposure to light at night lowers glucose-stimulated insulin secretion due to a decrease in insulin secretory pulse mass. Potential mechanisms have been identified by which disturbances in the circadian rhythms due to modern lifestyle can lead to islet failure in the type II diabetes [35] . It has also been reported that the impaired energy utilization from insulin deficiency impairs a longterm potentiation in diabetes [47] . 3.5.2. Pathway enrichment for the interacting proteins of the dataset "human pancreatic islets from normal and type II diabetic subjects (A)"
The protein B4GALT1, interacting with the identified protein FUT3 is involved in several metabolic pathways, connected to type II diabetes (Fig. 11 ). The protein B4GALT1 participates both in glycoconjugate and lactose biosynthesis. It has shown to be a biomarker in hepatocellular carcinoma, mainly caused due to the insulin resistance syndrome. Finally, the ailment manifests as obesity and later as diabetes [17] .
3.5.3. Pathway enrichment for the interacting proteins of the dataset "human pancreatic islets from normal and type II diabetic subjects (B)"
The protein PNPT1 interacting with the RNASEK is reported to be involved in pyrimidine and purine metabolism and the RNA degradation ( Fig. 12 ). Effects of the insulin regulation of purine and pyrimidine metabolism had shown to cause some late complications of the diabetic disease [34] . In 2009, Kocic et al. [20] reported that an impaired dsRNA metabolism may lead to increased levels of different sized RNAs in type II diabetic patients and may have an influence on further ineffective response against the different pathogens.
3.5.4. Pathway enrichment for the interacting proteins of dataset "human skeletal muscle-type II diabetes" EGFR protein interacting with the identified protein USP6NL has already been reported by many researchers to be involved in diabetes [1, 5, 27, 28, 41, 45] . With the pathway studies, it was identified that the main pathways in which EGFR is involved, is also leading directly to or indirectly to diabetes (Fig. 13 ). Hypoxia-inducible factor 1 alpha (HIF-1α) is regulated precisely by hypoxia and hyperglycemia. It had also been shown that the HIF-1α and glucose can sometimes influence each other [43] . It has been reported that the components of the MAPK/ERK pathway act as modifiers of the cellular insulin responsiveness. The insulin resistance was due to downregulation of the insulin-like receptor gene expression following persistent MAPK/ERK inhibition. The mechanism permits physiological adjustment of insulin sensitivity and the subsequent maintenance of the circulating glucose at appropriate levels [48] . MAPK and GnRh-Glp-1 pathways in the ileum have also been reported to be involved in the improvement of the blood glucose level [45] .
Conclusion
Analysis of type II diabetes expression data from two different tissue samples i.e. skeletal muscle and pancreatic islet has given a deep insight into genes which may be possibly involved in the pathophysiology of the disease. The most discriminatory genes obtained in each dataset after complete analysis, have been found to be associated with diabetes either directly or indirectly. However, the majority of the genes have not been previously reported in association with diabetes. The genes identified in the current study viz. FCGR2B, DLG3, SCNN1G, FUT3, HPRT1, APCDD1, USP6NL, ProSAPiP1 and RNASEK may act as a potential drug target. The significant pathways identified through the overall approach were Neuroactive ligand-receptor interaction, circadian entrainment, Long-term potentiation, pyrimidine and purine metabolism, dsRNA metabolism, MAPK/ERK pathway, and GnRh-Glp-1. This study gave the insight to focus on these associated pathways with the above-reported proteins to study in pathway models or mouse model to elucidate them as drug targets or markers for type II diabetes. 
